• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthWorld Health Organization

WHO reaffirms safety of Pfizer BioNTech vaccine for elderly patients after Norway scare

By
Naomi Kresge
Naomi Kresge
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Naomi Kresge
Naomi Kresge
and
Bloomberg
Bloomberg
Down Arrow Button Icon
January 22, 2021, 7:01 AM ET

The World Health Organization said it sees no evidence that Pfizer Inc. and BioNTech SE’s Covid-19 vaccine contributed to the deaths of elderly people and urged that the shot still be used.

Reports of deaths “are in line with the expected, all-cause mortality rates and causes of death in the sub-population of frail, elderly individuals, and the available information does not confirm a contributory role for the vaccine in the reported fatal events,” the WHO Global Advisory Committee on Vaccine Safety said in a statement on Friday. The risk-benefit balance of the vaccine “remains favorable in the elderly.”

The panel met on Tuesday to review reports that some very sick older people had died after getting the vaccine. Initial cases reported last week in Norway had raised alarm, with authorities saying it was possible that vaccine side-effects could aggravate underlying illnesses even as they expected some nursing-home residents to die shortly after being vaccinated due to their frail underlying health.

Norway moved to calm that anxiety on Monday, with the Norwegian Medicines Agency saying that Covid-19 is more dangerous to most patients than vaccination.

About the Authors
By Naomi Kresge
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.